Latest stories on EYPT
EyePoint updates DURAVYU Phase 3 wet AMD data
TipRanks56 · neutralproduct/pr
EyePoint, Inc. (EYPT) files 8-K
SEC 8-K50 · neutralgeneral
EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Seeking Alpha56 · neutralgeneral
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of EyePoint, Inc. - EYPT
Barchart50 · neutralgeneral
EyePoint, Inc. (NASDAQ: EYPT) Alert: Investors Encouraged to Contact KTMC Law Firm
GlobeNewswire50 · neutralgeneral
EYPT INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving EyePoint Pharmaceuticals
GlobeNewswire50 · neutralgeneral
EyePoint drops as TD Cowen becomes latest to downgrade on late-stage trial setback
Seeking Alpha32 · bearishanalyst
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
StockTitan56 · neutralgeneral
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
GlobeNewswire56 · neutralgeneral
EyePoint downgraded to Hold from Buy at TD Cowen
The Fly46 · neutralanalyst
TD Cowen downgrades EyePoint stock to Hold on trial concerns
Investing.com Analyst Ratings42 · neutralanalyst
EYPT ALERT: Investigation Launched into EyePoint, Inc., Investors are Encouraged to Contact KTMC Law Firm
PR Newswire34 · bearishgeneral
EyePoint After Lugano: Primary Endpoint Miss, Asymmetric Risk-Reward
Seeking Alpha56 · neutralproduct/pr
EYEPOINT PHARMACEUTICALS INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
GlobeNewswire34 · bearishgeneral
EyePoint Pharmaceuticals (EYPT) Securities Investigation Notice - Levi & Korsinsky
PR Newswire22 · bearishgeneral
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving EyePoint Pharmaceuticals (EYPT)
GlobeNewswire34 · bearishgeneral
EyePoint: Sell-Off As Duravyu Fails Head-To-Head Study Vs Eylea May Be Overblown
Seeking Alpha28 · bearishproduct/pr
EyePoint: Still A Sell After Phase 3 Crash
Seeking Alpha32 · bearishanalyst
EyePoint price target lowered to $20 from $43 at Jones
The Fly34 · bearishanalyst
EyePoint, Inc. (EYPT) Discusses LUGANO Top Line Data From Phase III Wet AMD Trial for DURAVYU Transcript
Seeking Alpha59 · neutralproduct/pr
EyePoint rebounds after selloff despite multiple downgrades
Seeking Alpha42 · neutralgeneral
DURAVYU’s Phase 3 LUGANO Results Reveal Compelling Efficacy and Reduced Treatment Burden in Wet AMD
August 18, 2026
MarketChameleon67 · bullishproduct/pr